GPR30: a novel indicator of poor survival for endometrial carcinoma

Harriet O. Smith, Kimberly K. Leslie, Meenakshi Singh, Clifford R. Qualls, Chetana M. Revankar, Nancy E. Joste, Eric R. Prossnitz

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

Objective: This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design: Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. Results: GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). Conclusion: GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.

Original languageEnglish (US)
JournalAmerican Journal of Obstetrics and Gynecology
Volume196
Issue number4
DOIs
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Survival
Estrogen Receptors
Progesterone
Progesterone Receptors
Epidermal Growth Factor Receptor
Neoplasms
Estrogens
Down-Regulation
Survival Rate
Immunohistochemistry

Keywords

  • endometrial carcinoma
  • estrogen receptor
  • GPR30
  • progesterone receptor
  • survival

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Smith, H. O., Leslie, K. K., Singh, M., Qualls, C. R., Revankar, C. M., Joste, N. E., & Prossnitz, E. R. (2007). GPR30: a novel indicator of poor survival for endometrial carcinoma. American Journal of Obstetrics and Gynecology, 196(4). https://doi.org/10.1016/j.ajog.2007.01.004

GPR30 : a novel indicator of poor survival for endometrial carcinoma. / Smith, Harriet O.; Leslie, Kimberly K.; Singh, Meenakshi; Qualls, Clifford R.; Revankar, Chetana M.; Joste, Nancy E.; Prossnitz, Eric R.

In: American Journal of Obstetrics and Gynecology, Vol. 196, No. 4, 04.2007.

Research output: Contribution to journalArticle

Smith, HO, Leslie, KK, Singh, M, Qualls, CR, Revankar, CM, Joste, NE & Prossnitz, ER 2007, 'GPR30: a novel indicator of poor survival for endometrial carcinoma', American Journal of Obstetrics and Gynecology, vol. 196, no. 4. https://doi.org/10.1016/j.ajog.2007.01.004
Smith, Harriet O. ; Leslie, Kimberly K. ; Singh, Meenakshi ; Qualls, Clifford R. ; Revankar, Chetana M. ; Joste, Nancy E. ; Prossnitz, Eric R. / GPR30 : a novel indicator of poor survival for endometrial carcinoma. In: American Journal of Obstetrics and Gynecology. 2007 ; Vol. 196, No. 4.
@article{ce1cfaf5126247dfbde7ce7db941352c,
title = "GPR30: a novel indicator of poor survival for endometrial carcinoma",
abstract = "Objective: This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design: Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. Results: GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2{\%} vs 100{\%}, P = .005). Conclusion: GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.",
keywords = "endometrial carcinoma, estrogen receptor, GPR30, progesterone receptor, survival",
author = "Smith, {Harriet O.} and Leslie, {Kimberly K.} and Meenakshi Singh and Qualls, {Clifford R.} and Revankar, {Chetana M.} and Joste, {Nancy E.} and Prossnitz, {Eric R.}",
year = "2007",
month = "4",
doi = "10.1016/j.ajog.2007.01.004",
language = "English (US)",
volume = "196",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - GPR30

T2 - a novel indicator of poor survival for endometrial carcinoma

AU - Smith, Harriet O.

AU - Leslie, Kimberly K.

AU - Singh, Meenakshi

AU - Qualls, Clifford R.

AU - Revankar, Chetana M.

AU - Joste, Nancy E.

AU - Prossnitz, Eric R.

PY - 2007/4

Y1 - 2007/4

N2 - Objective: This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design: Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. Results: GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). Conclusion: GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.

AB - Objective: This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design: Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. Results: GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). Conclusion: GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.

KW - endometrial carcinoma

KW - estrogen receptor

KW - GPR30

KW - progesterone receptor

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=33947697810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947697810&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2007.01.004

DO - 10.1016/j.ajog.2007.01.004

M3 - Article

C2 - 17403429

AN - SCOPUS:33947697810

VL - 196

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 4

ER -